BofA analyst Tim Anderson raised the firm’s price target on Aardvark Therapeutics (AARD) to $26 from $22 and keeps a Buy rating on the shares after Soleno Therapeutics (SLNO), a competitor to Aardvark, received FDA approval for treating hyperphagia associated with Prader-Willi syndrome in patients 4 and older under the brand name Vykat XR. The firm views the competitor’s news “favorably” for Aardvark and as partially de-risking for ARD101.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AARD:
- Aardvark Therapeutics initiated with an Overweight at Cantor Fitzgerald
- Aardvark Therapeutics initiated with an Outperform at RBC Capital
- Aardvark Therapeutics initiated with a Buy at BofA
- Aardvark Therapeutics initiated with an Overweight at Morgan Stanley
- Opening Day: Kestra opens for trading, Discord discusses potential IPO